Literature DB >> 21331621

Genetic variants in ultraconserved elements and risk of breast cancer in Chinese population.

Hao Shen1, Cheng Lu, Yue Jiang, Jinhai Tang, Wei Chen, Hanze Zhang, Qin Zhang, Jianming Wang, Jie Liang, Zhibin Hu, Hongbing Shen.   

Abstract

Ultraconserved elements (UCEs) are the most extreme representatives of conserved non-coding sequences. Recent studies have indicated that UCEs are not mutation cold regions and likely to be concerned with cancers, including breast cancer (BC). In this study, we first screened common single-nucleotide polymorphisms (SNPs) (minor allele frequency, MAF > 0.05) in Chinese population located in 481 UCEs sequences and selected seven SNPs (rs17049105, rs13020355, rs2682406, rs2056116, rs11190870, rs9572903, and rs8004379) of uc.51, uc.82, uc.133, uc.140, uc.302, uc.353, and uc.368, respectively. A two-stage case-control study of BC with a total of 1,497 cases and 1,497 controls in Chinese population was conducted to test the hypothesis that these SNPs of UCEs are associated with BC risk. Stage I with 735 cases and 735 controls was designed to discover the risk variants, followed by stage II with 762 cases and 762 controls to validate the significant variants. In stage I, although the genotype distributions of all seven SNPs were not significantly different between BC cases and controls, logistic regression analyses revealed that the variant genotypes of rs8004379 were significantly associated with the increased risk of BC (dominant model: adjusted OR = 1.27, 95% CI = 1.01-1.58, P = 0.039). We then selected two SNPs, rs8004379 A/C and rs2056116 A/G, with lowest P values of the associations into the stage II analysis. However, none of above two SNPs were significantly associated with BC risk in both stage II and pooled set (rs8004379 AC/CC vs. AA: adjusted OR = 0.88, 95% CI = 0.68-1.13 for stage II and adjusted OR = 1.09, 95% CI = 0.92-1.29 for the pooled set; rs2056116 AG/GG vs. AA: adjusted OR = 1.12, 95% CI = 0.87-1.45 for stage II and adjusted OR = 1.11, 95% CI = 0.94-1.31 for the pooled set). These findings did not support a significant association between UCEs SNPs and the risk of BC in Chinese population.

Entities:  

Mesh:

Year:  2011        PMID: 21331621     DOI: 10.1007/s10549-011-1395-4

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  6 in total

Review 1.  Long non-coding RNAs and cancer: a new frontier of translational research?

Authors:  R Spizzo; M I Almeida; A Colombatti; G A Calin
Journal:  Oncogene       Date:  2012-01-23       Impact factor: 9.867

Review 2.  Long Noncoding RNAs in the Pathogenesis of Barrett's Esophagus and Esophageal Carcinoma.

Authors:  John M Abraham; Stephen J Meltzer
Journal:  Gastroenterology       Date:  2017-05-18       Impact factor: 22.682

3.  Genetic Variations of Ultraconserved Elements in the Human Genome.

Authors:  Anamarija Habic; John S Mattick; George Adrian Calin; Rok Krese; Janez Konc; Tanja Kunej
Journal:  OMICS       Date:  2019-11

4.  Analysis of Long Non-Coding RNA (lncRNA) uc.38 and uc.63 Expression in Breast Carcinoma Patients.

Authors:  Anna Zadrożna-Nowak; Hanna Romanowicz; Marek Zadrożny; Magdalena Bryś; Ewa Forma; Beata Smolarz
Journal:  Genes (Basel)       Date:  2022-03-28       Impact factor: 4.141

Review 5.  Transcribed Ultraconserved Regions in Cancer.

Authors:  Myron K Gibert; Aditya Sarkar; Bilhan Chagari; Christian Roig-Laboy; Shekhar Saha; Sylwia Bednarek; Benjamin Kefas; Farina Hanif; Kadie Hudson; Collin Dube; Ying Zhang; Roger Abounader
Journal:  Cells       Date:  2022-05-19       Impact factor: 7.666

6.  Transcribed ultraconserved noncoding RNAs (T-UCR) are involved in Barrett's esophagus carcinogenesis.

Authors:  Matteo Fassan; Luigi Dall'Olmo; Marco Galasso; Chiara Braconi; Marco Pizzi; Stefano Realdon; Stefano Volinia; Nicola Valeri; Pierluigi Gasparini; Raffaele Baffa; Rhonda F Souza; Caterina Vicentini; Edoardo D'Angelo; Jan Bornschein; Gerard J Nuovo; Giovanni Zaninotto; Carlo M Croce; Massimo Rugge
Journal:  Oncotarget       Date:  2014-08-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.